FierceBiotech Names QurAlis as One of the “Fierce 15” Biotech Companies of 2020  

This Monday, FierceBiotech has announced the winners of its annual “Fierce 15” nomination, which highlights the most promising private biotechnology companies in the industry. Inkef’s portfolio company QurAlis was selected as one of the winners, FierceBiotech commented on what makes the company Fierce: “QurAlis aims to zero in on precision treatments by using the understanding of genetics in ALS, and new stem cell technology from Harvard University’s Kevin Eggan, Ph.D., who made the first stem cells from ALS patients and turned those into motor neurons.” For the full article, please visit https://www.fiercebiotech.com/special-report/quralis-fierce-biotech-s-2020-fierce-15